| 综述 |
|
|
|
|
| 帕金森病和阿尔茨海默氏病的基因治疗研究进展 |
| 凡复1,2, 陈建国1, 任宏伟1,2 |
1. 北京大学生命科学学院 北京 100871;
2. 厦门北大之路生物工程有限公司研发中心 厦门 361009 |
|
| Development of Gene Therapy for Parkinson’s Disease And Alzheimer’s Disease |
| FAN Fu1,2, CHEN Jian-guo1, REN Hong-wei1,2 |
1. School of Life Sciences, Peking University, Beijing 100871, China;
2. R&D Center of Xiamen Bioway Biotech. Co. LTD., Xiamen 361009, China |
[1] Dauer W, Przedborski S. Parkinson’s disease: mechanisms and model. Neuron, 2003, 39(6): 889-909.
[2] Rui J N, Luís P A. Gene therapy for Parkinson’s and Alzheimer’s diseases: from the bench to clinical trials. Current Pharmaceutical Design, 2011, 17(31): 3434-3445.
[3] Jankovic J. Complications and limitations of drug therapy for Parkinson’s disease. Neurology, 2000, 55(12 Suppl 6): S2-6.
[4] Azzouz M, Martin-Rendon E, Barber R D, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson’s disease. J Neurosci, 2002, 22(23): 10302-103012.
[5] Muramatsu S, Fujimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther, 2002, 13(3): 345-354.
[6] Shen Y, Muramatsu S I, Ikeguchi K, et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson’s disease. Hum Gene Ther, 2000, 11(11): 1509-1519.
[7] Oxford bioMedica announces top-line results from six month follow-up of third patient cohort in ProSavin? Phase I/II study in Parkinson’s disease. Oxford Biomedica press release, 2011, http://www.oxfordbiomedica.co.uk/page.asp?pageid= 59&newsid=287.
[8] Bankiewicz K S, Forsayeth J, Eberling J L, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther, 2006, 14(4): 564-5670.
[9] Hadaczek P, Eberling J L, Pivirotto P, et al. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther, 2010, 18(8): 1458-1461.
[10] Muramatsu S, Fujimoto K, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease. Mol Ther, 2010, 18(9): 1731-1735.
[11] Lin L F, Doherty D H, Lile J D, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 1993, 260(5111): 1130-1132.
[12] Chen Y H, Harvey B K, Hoffman A F, et al. MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J, 2008, 22:261-275.
[13] Eberling J L, Kells A P, Pivirotto P, et al. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in Parkinsonian rhesus monkeys. Hum Gene Ther, 2009, 20:511-518.
[14] Johnston L C, Eberling J, Pivirotto P, et al. Clinically relevant effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged Rhesus monkeys. Hum Gene Ther, 2009, 20(5):497-510.
[15] Brizard M, Carcenac C, Bemelmans A P, et al. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson’s disease. Neurobiol Dis, 2006, 21:90-101.
[16] Palfi S, Leventhal L, Chu Y, et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci, 2002, 22:4942-4954.
[17] Smith A D, Kozlowski D A, Bohn M C, et al. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp Neurol, 2005, 193(2):420-426.
[18] Sun M, Kong L, Wang X, et al. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Res, 2005, 1052:119-129.
[19] Huang R Q, Ke W L, Liu Y, et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci, 2009, 29(1-2):123-130.
[20] Rosenblad C, Georgievska B, Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci, 2003, 17(2):260-270.
[21] Sajadi A, Bauer M, Thony B, et al. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J Neurochem, 2005, 93(6):1482-1486.
[22] Gasmi M, Brandon E P, Herzog C D, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson’s disease. Neurobiol Dis, 2007, 27(1):67-76.
[23] Gasmi M, Herzog C D, Brandon E P, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease. Mol Ther, 2007, 15(1):62-68.
[24] Herzog C D, Brown L, Gammon D, et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson’s disease. Neurosurgery, 2009, 64(4):603-612.
[25] Herzog C D, Dass B, Gasmi M, et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther, 2008, 16(10):1737-1744.
[26] Luo J, Kaplitt M G, Fitzsimons H L, et al. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science, 2002, 298(5592): 425-429.
[27] Emborg M E, Carbon M, Holden J E, et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab, 2007, 27(3): 501-509.
[28] Kaplitt M G, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus(AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet, 2007, 369(9579): 2097-2105.
[29] Singleton A B, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 2003, 302(5646): 841.
[30] Nishioka K, Hayashi S, Farrer M J, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol, 2006, 59(2): 298-309.
[31] Bellucci A, Navarria L, Zaltieri M, et al. Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson’s disease. Brain Research. 2012, 1432(1): 95-113.
[32] Fountaine T M, Wade-Martins R. RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res, 2007, 85(2): 351-363.
[33] Han Y, Khodr C E, Sapru M K, et al. A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. Brain Res, 2011, 1386: 15-24.
[34] Khandelwal P J, Dumanis S B, Feng L R, et al. Parkinson-related parkin reduces alpha-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener, 2010, 5: 47.
[35] Nascimento-Ferreira I, Santos-Ferreira T, Sousa-Ferreira L, et al. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain, 2011, 134(Pt 5): 1400-1415.
[36] Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci, 1991, 12(10): 383-388.
[37] Tanzi R E, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell, 2005, 120(4): 545-555.
[38] Selkoe D J. Clearing the brain’s amyloid cobwebs. Neuron, 2001, 32(2): 177-180.
[39] Levi-Montalcini R. The nerve growth factor 35 years later. Science, 1987, 237(4819): 1154-1162.
[40] Lapchak P A, Araujo D M, Carswell S, et al. Distribution of nerve growth factor in the rat brain following a single intraventricular injection: correlation with the topographical distribution of trkA messenger RNA-expressing cells. Neuroscience, 1993, 54(2):445-460.
[41] Kromer L F. Nerve growth factor treatment after brain injury prevents neuronal death. Science, 1987, 235(4785): 214-216.
[42] Tuszynski M H, Sang H, Yoshida K, et al. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol, 1991, 30(5): 625-636.
[43] Eriksdotter Jonhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement Geriatr Cogn Disord, 1998, 9(5): 246-257.
[44] Rosenberg M B, Friedmann T, Robertson R C, et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science, 1988, 242(4885): 1575-1578.
[45] Tuszynski M H, Roberts J, Senut M C, et al. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther, 1996, 3(4): 305-314.
[46] Smith D E, Roberts J, Gage F H, et al. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA, 1999, 96(19): 10893-10898.
[47] Conner J M, Darracq M A, Roberts J, et al. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci USA, 2001, 98(4): 1941-1946.
[48] Tuszynski M H, Thal L, Pay M, et al. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med, 2005, 11(5): 551-555.
[49] Advanced encapsulated cell biodelivery product for Alzheimer’s disease successfully implanted in six patients. NsGene press release, 2008; http://nsgene.dk/NsGene-5.aspx?M=News&PID=15&NewsID=40.
[50] Nicoll J A, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med, 2003, 9(4): 448-452.
[51] Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634): 216-223.
[52] Liu M, Acres B, Balloul J M, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA, 2004, 101(Suppl 2): 14567-14571.
[53] Bowers W J, Mastrangelo M A, Stanley H A, et al. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol Aging, 2005, 26(4): 393-407.
[54] Levites Y, Jansen K, Smithson L A, et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci, 2006, 26(46): 11923-11928.
[55] Ryan D A, Mastrangelo M A, Narrow W C, et al. Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer’s disease mice. Mol Ther, 2010, 18(8): 1471-1481.
[56] Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med, 2000, 6(2): 143-150.
[57] Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science, 2001, 292(5521): 1550-1552.
[58] Marr R A, Rockenstein E, Mukherjee A, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci, 2003, 23(6): 1992-1996.
[59] Hong C S, Goins W F, Goss J R, et al. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer’s disease-related amyloid-beta peptide in vivo. Gene Ther, 2006, 13(14): 1068-1079.
[60] Lebson L, Nash K, Kamath S, et al. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci, 2010, 30(29): 9651-9658.
[61] Selkoe D J, Schenk D. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol, 2003, 43: 545-584.
[62] Holsinger R M, McLean C A, Beyreuther K, et al. Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol, 2002, 51(6): 783-786.
[63] Singer O, Marr R A, Rockenstein E, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci, 2005, 8(10): 1343-1349.
[64] Gong C X, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem, 2008, 15(23): 2321-2328.
[65] Mazanetz M P, Fischer P M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov, 2007, 6(6): 464-479.
[66] Piedrahita D, Hernandez I, Lopez-Tobon A, et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer’s mice. J Neurosci, 2010, 30(42): 13966-13976.
[67] Wolozin B. Cholesterol and the biology of Alzheimer’s disease. Neuron, 2004, 41(1): 7-10.
[68] Puglielli L, Tanzi R E, Kovacs D M. Alzheimer’s disease: the cholesterol connection. Nat Neurosci, 2003, 6(4): 345-351.
[69] Lund E G, Guileyardo J M, Russell D W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA, 1999, 96(13): 7238-7243.
[70] Hudry E, Van Dam D, Kulik W, et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease. Mol Ther, 2010, 18(1): 44-53.
[71] Manfredsson F P, Bloom D C, Mandel R J. Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues. Neurobiology of Disease, 2012, 48: 212-221. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
